Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer

PHASE3RecruitingINTERVENTIONAL

Enrollment

328

Participants

Timeline

Start Date

October 6, 2021

Primary Completion Date

September 30, 2024

Study Completion Date

December 31, 2024

Conditions

Differentiated Thyroid Cancer

Interventions

BIOLOGICAL

rhTSH

rhTSH (0.9 mg) was administered intramuscularly (IM) once daily (qd) for 2 days. Twenty-four hours following the second dose of rhTSH

RADIATION

Radioiodine (131I)

Patients were given an ablative dose of 131I (30 mCi±1.5 mCi).

Trial Locations (1)

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors

lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY